PMID- 34514991
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20221207
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Linking)
VI  - 18
IP  - 4
DP  - 2022
TI  - Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination 
      for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized 
      Controlled Trials and Observational Studies.
PG  - e100921196392
LID - 10.2174/1573399817666210910165402 [doi]
AB  - BACKGROUND: Treatment of diabetes mellitus includes more than one drug of 
      different groups, which may lead to a high pill burden and non-adherence to 
      drugs. We have aimed to systematically analyze the clinical efficacy, safety, and 
      pharmacoeconomic cost-effectiveness of the fixed-dose combination of 
      empagliflozin plus a linagliptin in Type-2 Diabetes mellitus (T2DM) patients. 
      METHODS: A literature search of PubMed/MEDLINE, SCOPUS, Google Scholar, and 
      EMBASE was performed using the MeSH terms and/or keywords"((Single-pill 
      combination) OR ((Fixeddose combination) OR (Combination therapy)) AND 
      (Empagliflozin add on-to Linagliptin) OR (Empagliflozin combined with 
      Linagliptin) OR ((Combination of Empagliflozin and Linagliptin)" from the 
      inception to February 2021. RESULTS: Search results were found in a total of 13 
      clinical studies. After removing duplicates and studies not according to 
      inclusion criteria, a total of eight clinical studies (Randomized controlled 
      trials: 7; Observational cohort studies: 1) were included (n=7491). A significant 
      reduction in the primary endpoint, the mean changes in baseline HbA1c at the end 
      of 24 weeks and/or 52 weeks was found in the empagliflozin plus a linagliptin 
      combination group in all included studies. In addition, significant efficacy was 
      seen in decreasing the secondary endpoints such as the mean change in the fasting 
      plasma glucose, systolic and diastolic blood pressure (DBP), and body weight with 
      fewer adverse events than the adverse effects with either drug alone. CONCLUSION: 
      After reviewing findings from the available clinical studies of the combination 
      of empagliflozin plus linagliptin, we conclude that the combination is effective, 
      safe, tolerable, and rationale cost effective compared to placebo and either drug 
      alone for the management of T2DM in patients with inadequate glycemic control 
      with metformin alone, patients with intolerance to metformin, increased baseline 
      HbA1c, patients with overweight or obesity and diabetic hypertensive, CHF, 
      atherosclerotic cardiovascular disease, and renal dysfunction patients. Future 
      randomized controlled trials in a larger number of T2DM patients with or without 
      CHF and renal failure patients are recommended.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Chenchula, Santenna
AU  - Chenchula S
AD  - Department of Pharmacology, All India Institute of Medical Sciences Bhopal, 
      India.
FAU - Varthya, Shoban Babu
AU  - Varthya SB
AD  - Department of Pharmacology, All India Institute of Medical Sciences Jodhpur, 
      India.
FAU - Padmavathi, R
AU  - Padmavathi R
AD  - Junior Resident, SVSMCH, Hyderabad, India.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United Arab Emirates
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 3X29ZEJ4R2 (Linagliptin)
RN  - 9100L32L2N (Metformin)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/adverse effects
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2
MH  - Drug Therapy, Combination
MH  - Glucosides
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Linagliptin/adverse effects
MH  - *Metformin/therapeutic use
MH  - Observational Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
OTO - NOTNLM
OT  - DPP-4 Inhibitors
OT  - Empagliflozin plus linagliptin
OT  - SGLT 2 Inhibitors
OT  - Type2 diabetes mellitus
OT  - cardiac
OT  - glycated hemoglobin
OT  - rationality
OT  - renal safety
EDAT- 2021/09/14 06:00
MHDA- 2022/05/18 06:00
CRDT- 2021/09/13 09:01
PHST- 2021/04/05 00:00 [received]
PHST- 2021/08/12 00:00 [revised]
PHST- 2021/08/16 00:00 [accepted]
PHST- 2021/09/14 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2021/09/13 09:01 [entrez]
AID - CDR-EPUB-117876 [pii]
AID - 10.2174/1573399817666210910165402 [doi]
PST - ppublish
SO  - Curr Diabetes Rev. 2022;18(4):e100921196392. doi: 
      10.2174/1573399817666210910165402.